John D. McCorvy
YOU?
Author Swipe
View article: Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights
Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights Open
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD), resulting in breakthrough status. However, concerns regarding MDMA's abuse potential and c…
View article: A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide
A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide Open
The complement 3a receptor (C3aR) is a G-protein-coupled receptor (GPCR) involved in inflammatory, metabolic, and neurological diseases. Two endogenous ligands (C3a and TLQP-21) and small molecules (SB290157 and JR14a) differentially signa…
View article: Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice
Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice Open
Summary Microdosing, the prolonged ingestion of psychedelics at sub-hallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT 2B receptors, which cause heart di…
View article: Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson’s disease and its comorbidities
Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson’s disease and its comorbidities Open
Parkinson's disease (PD) treatment focuses mainly on the augmentation of dopamine transmission, but to alleviate adverse motor effects accompanying L-DOPA use, additional treatments with serotonergic (5-HT) medications may be considered. W…
View article: Bioisosteric analogs of <scp>MDMA</scp> : Improving the pharmacological profile?
Bioisosteric analogs of <span>MDMA</span> : Improving the pharmacological profile? Open
3,4‐Methylenedioxymethamphetamine (MDMA, ‘ ecstasy’ ) is re‐emerging in clinical settings as a candidate for the treatment of specific neuropsychiatric disorders (e.g. post‐traumatic stress disorder) in combination with psychotherapy. MDMA…
View article: Bioisosteric analogs of MDMA with improved pharmacological profile
Bioisosteric analogs of MDMA with improved pharmacological profile Open
3,4-Methylenedioxymethamphetamine (MDMA, ‘ ecstasy’ ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a…
View article: Functional profiling of the G protein-coupled receptor C3aR1 reveals ligand-mediated biased agonism
Functional profiling of the G protein-coupled receptor C3aR1 reveals ligand-mediated biased agonism Open
G protein-coupled receptors (GPCRs) are leading druggable targets for several medicines, but many GPCRs are still untapped for their therapeutic potential due to poor understanding of specific signaling properties. The complement C3a recep…
View article: Beyond the 5-HT<sub>2A</sub>Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action
Beyond the 5-HT<sub>2A</sub>Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action Open
Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects and unique mechanisms of action. These compounds exert their primary effects through activat…
View article: Identification of 5-HT<sub>2A</sub>Receptor Signaling Pathways Responsible for Psychedelic Potential
Identification of 5-HT<sub>2A</sub>Receptor Signaling Pathways Responsible for Psychedelic Potential Open
Summary Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT 2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT 2A -Gq/11 and β-arrestin2 signaling, making their…
View article: Mu-opioid receptor selective superagonists produce prolonged respiratory depression
Mu-opioid receptor selective superagonists produce prolonged respiratory depression Open
Synthetic opioids are increasingly challenging to combat the opioid epidemic and act primarily at opioid receptors, chiefly the G protein-coupled receptor (GPCR) μ-opioid receptor (MOR), which signals through G protein-dependent and β-arre…
View article: Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors Open
Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric diseases, and the ability to promote cortical neuron growth has been hypothesized to underlie the rapid and sustained therapeutic effects of psychede…
View article: Molecular and cellular basis of praziquantel action in the cardiovascular system
Molecular and cellular basis of praziquantel action in the cardiovascular system Open
The anthelmintic drug praziquantel (PZQ) causes contraction of parasitic schistosomes as well as constriction of blood vessels within the mesenteric vasculature of the host where the adult blood flukes reside. The contractile action of PZQ…
View article: Pharmacological Mechanism of the Non-hallucinogenic 5-HT<sub>2A</sub> Agonist Ariadne and Analogs
Pharmacological Mechanism of the Non-hallucinogenic 5-HT<sub>2A</sub> Agonist Ariadne and Analogs Open
Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group…
View article: DPP4-Truncated CXCL12 Alters CXCR4/ACKR3 Signaling, Osteogenic Cell Differentiation, Migration, and Senescence
DPP4-Truncated CXCL12 Alters CXCR4/ACKR3 Signaling, Osteogenic Cell Differentiation, Migration, and Senescence Open
Bone marrow skeletal stem cells (SSCs) secrete many cytokines including stromal derived factor-1 or CXCL12, which influences cell proliferation, migration, and differentiation. All CXCL12 splice variants are rapidly truncated on their N-te…
View article: CCDC 2093535: Experimental Crystal Structure Determination
CCDC 2093535: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: CCDC 2093536: Experimental Crystal Structure Determination
CCDC 2093536: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: CCDC 2093770: Experimental Crystal Structure Determination
CCDC 2093770: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: CCDC 2093534: Experimental Crystal Structure Determination
CCDC 2093534: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …